MUFG Americas’s Alnylam Pharmaceuticals ALNY Stock Holding History

MUFG Americas’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,880	Closed	-$376K	–	30
2022 Q3	$376K	Buy	1,880 +13	+0.7%	+$2.48K	0.01%	328
2022 Q2	$272K	Buy	1,867 +51	+3%	+$7.24K	0.01%	359
2022 Q1	$297K	Buy	1,816 +61	+3%	+$9.29K	0.01%	357
2021 Q4	$298K	Buy	1,755 +89	+5%	+$16.5K	0.01%	362
2021 Q3	$315K	Buy	1,666 +8	+0.5%	+$1.5K	0.01%	351
2021 Q2	$281K	Buy	1,658 +418	+34%	+$61.2K	﹤0.01%	365
2021 Q1	$175K	Buy	1,240 +266	+27%	+$40K	﹤0.01%	414
2020 Q4	$127K	Buy	974 +250	+35%	+$33.4K	﹤0.01%	430
2020 Q3	$106K	Buy	724 +166	+30%	+$23.6K	﹤0.01%	428
2020 Q2	$82K	Buy	+558	New	+$75.2K	﹤0.01%	442
2013 Q3	–	Sell	-3,200	Closed	-$99K	–	1182
2013 Q2	$99K	Buy	+3,200	New	+$85.2K	﹤0.01%	1041

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MUFG Americas's ALNY Position: Q4 2022 in Review

MUFG Americas sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2022, closing a stake of 1,880 shares — an estimated $376K sold.

MUFG Americas first reported a position in ALNY in Q2 2013 and held it in 11 quarters. The position peaked at $376K in Q3 2022. 487 funds tracked by Wall St. Rank hold ALNY as of Q4 2022.

MUFG Americas reported no remaining Alnylam Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
MUFG Americas sold 1,880 Alnylam Pharmaceuticals shares in Q4 2022, an estimated $376K.
MUFG Americas first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 11 quarters.
MUFG Americas's Alnylam Pharmaceuticals position peaked at $376K in Q3 2022.
487 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2022.

Based on MUFG Americas's 13F filing for Q4 2022.